Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Demographic data, clinical findings, and outcomes

From: Focused cardiopulmonary ultrasound for assessment of dyspnea in a resource-limited setting

  Total patients N = 117 Pediatric (<18 years) N = 29 Adult (>18 years) N = 88
Female 65 (56 %) 11 (38 %) 54 (61 %)
Comorbid conditions
Tobacco 9 (8 %) 0 9 (10 %)
Post-partum 8 (7 %) 0 8 (9 %)
Tuberculosis 5 (4 %) 0 5 (6 %)
HIV 5 (4 %) 1 4 (5 %)
Diabetes mellitus 2 (2 %) 0 2 (2 %)
Clinical findings
Tachypnea (n = 88) 88 (100 %) NA* 88 (100 %)
Tachycardia (n = 86) 57 (66 %) NA* 57 (66 %)
Abnormal lung exam 83 (71 %) 27 (93 %) 56 (63 %)
Peripheral edema 44 (38 %) 0 44 (50 %)
Outcomes
Hospitalized 95 (81 %) 28 (97 %) 67 (76 %)
Median/IQR length of hospital stay (days) 6/6 (n = 92) 6/4 (n = 26) 6/8 (n = 66)
Death during hospitalization 17 (15 %) 0 17 (19 %)
  1. Data are reported as number of patients (percentage)
  2. Post-partum is defined as delivery in the prior 6 months. Abnormal vital signs (tachypnea and tachycardia) are reported for adults only. Tachypnea is defined as respiratory rate >20 breaths per minute. Tachycardia is defined as heart rate >100 beats per minute. Abnormal lung exam was defined as decreased breath sounds, wheezes, crackles, and/or rhonchi, though was left to the interpretation of the treating clinician at the time of the exam. Pediatric heart rate and respiratory rate were recorded however given variability of vital signs with change in age, we did not define tachycardia/tachypnea for children
  3. All percentages have been rounded to the nearest whole percent
  4. HIV human immunodeficiency virus, IQR interquartile range, NA not applicable